about
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutationsEx vivo analysis identifies effective HIV-1 latency-reversing drug combinations.HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapyA National Study of Outcomes among HIV-Infected Kidney Transplant RecipientsLong-term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus-Infected Recipients.Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesEpidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience.Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors.Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.HIV-1 and hematopoietic stem cell transplantation.Developing strategies for HIV-1 eradicationHematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication.Pasteurella multocida infection in solid organ transplantation.New modalities in the treatment of HCV in pre and post - transplantation setting.Challenges and Clinical Decision-Making in HIV-to-HIV Transplantation: Insights From the HIV Literature.Hepatitis C following liver transplantation: current approach and future research opportunities.Access to Kidney Transplantation among HIV-Infected Waitlist Candidates.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Epstein-Barr virus and renal transplantation.HIV and Stem Cell Transplantation.Survival Benefit of Kidney Transplantation in HIV-infected Patients.Utilization of Hepatitis C RNA-positive Donor Liver for Transplant to Hepatitis C RNA-Negative Recipient.Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors.Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma.Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience.False-positive hepatitis C virus serology after placement of a ventricular assistance device.Center-Level Experience and Kidney Transplant Outcomes in HIV-Infected Recipients.HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia.Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA).A Human Immunodeficiency Virus Controller With a Large Population of CD4(+)CD8(+) Double-Positive T Cells.HIV cure: knocking on the door.Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapyTranscriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection.HIV+ Deceased Donor Referrals: A National Survey of Organ Procurement Organizations.Expanding the Use of Organs from Hepatitis C-Viremic Donors: The Evidence Continues to Build.
P50
Q35237575-36F11C0D-7CFE-47CF-9599-B4F9EF68D00EQ35521811-DD98781C-9C8E-4162-B4E1-3F5D151877E0Q35720063-188E8163-2E9A-414F-A7E3-42EFD52B3C0EQ35766026-1C9F926B-2ABF-416F-AA5E-67E004766A17Q36003147-3EF976D6-2EE2-45C7-AF39-5F68534479F2Q36385149-1071E958-7270-4833-BD7C-1874487F0E84Q36409885-A3664B0F-EF57-4707-9005-CE2043632A23Q36825808-F90D342F-AA2C-4787-AAE0-FA2FCEAB8D92Q36876327-ED77ACBD-D008-4D7F-9203-5C2D647E7399Q37104335-85A24E71-9C4E-442B-A6CB-E759C09364DBQ37552703-5E054C08-1244-4F71-A7F2-E3CA55E101CFQ37695001-1D7D77F5-8C66-4912-BB5D-92C112401867Q37973860-E85D5FF7-C481-433B-A48D-0D5EBAA16EC3Q38032363-3A9FAFA7-0F35-486B-84BB-54DC872B0D0AQ38079497-33D9F506-1E9D-480C-83D6-D5A870856640Q38281775-ECB97725-241D-41F6-97E8-991D1F1981F8Q38501360-548613FA-7DEF-4D9C-954B-5C367937458DQ38529520-D5694E80-59A9-43C5-AE2B-5CE9762BAE7CQ38837215-7774ECB3-65A1-4DCA-AB65-5125A8786558Q38945249-09221F28-05FB-4606-92EC-E1C145F3FEADQ39007700-01CC7404-C429-4D12-9CD5-8C82F3E7E8B2Q39089470-25669E6D-B86C-4B21-B63A-07DEEC887C9EQ39145369-681823F9-F5A1-47E2-809C-D81C7B1F9EE5Q39262004-C693A0B3-9925-40CA-A7CF-766D39DF5BF0Q40105607-92E079E8-80FA-4716-80AD-6707C7862C47Q40204367-7D2F0A07-DBE1-481C-978A-DAB35DDA4DC8Q40328430-A01C9449-7FFB-4EA4-A091-D9A5655DE797Q40600331-6EE75626-A2C4-44FF-8CC9-4D5DDC276DDBQ40700444-24518B02-3F42-460A-9A82-96752921A75CQ40881352-E680AA60-4A75-48BF-AE25-E098F46B0D1DQ41125856-2139A1CA-667F-49BE-A496-8AE36367FF6BQ41216499-909EC257-7B19-4F61-A17E-777A5570FA5CQ41811743-57CD4D6D-6A43-42B4-95FE-2D4629EF3E29Q41932462-75D07DFB-D4E4-46AB-9336-8183F4C2AD86Q42121597-C2BE713B-3F46-44B4-B04A-B5263607C78BQ42266102-956779E8-5C3A-4A3C-AAD3-C52412A24F6AQ42763396-97D0C0D6-749F-450F-9B3F-858510FCCD07Q44876281-F7FE4936-0649-4723-9F29-AB174472125AQ47338813-9C2E5174-6E6D-446D-B1C6-C01FC7E3296AQ49618177-5C308B16-7112-41E7-8991-0749B703BFD6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christine M. Durand
@ast
Christine M. Durand
@en
Christine M. Durand
@es
Christine M. Durand
@nl
Christine M. Durand
@sl
type
label
Christine M. Durand
@ast
Christine M. Durand
@en
Christine M. Durand
@es
Christine M. Durand
@nl
Christine M. Durand
@sl
prefLabel
Christine M. Durand
@ast
Christine M. Durand
@en
Christine M. Durand
@es
Christine M. Durand
@nl
Christine M. Durand
@sl
P106
P1153
25927839100
P21
P31
P496
0000-0003-2605-9257